Fuad El-Hibri

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced that it has completed the acquisition of a 55,000-square-foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the city of Baltimore.

Daniel J. Abdun-Nabi

ROCKVILLE, MD. —Emergent BioSolutions Inc. announced that dosing of patients has begun in a U.S. Phase II clinical trial of the company’s single-dose oral typhoid vaccine candidate.

Typhoid

ROCKVILLE, Md. — Emergent BioSolutions Inc. announced that its single-dose, drinkable typhoid vaccine candidate was highly immunogenic and well-tolerated with an acceptable safety profile in the population studied.

Dr Steven Chatfield

GAITHERSBURG, Md. —Emergent BioSolutions Inc. announced the commencement of dosing of volunteer subjects in a clinical study in Ho Chi Minh City, Vietnam, to evaluate the safety and immunogenicity of the company’s single-dose oral typhoid vaccine.

Fuad El-Hibri

GAITHERSBURG, Md. — Emergent BioSolutions announced that it acquired England-based Microscience Ltd., a privately held vaccine company primarily involved in the research and development of proprietary vaccines and immunotherapeutics.